Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc to Discuss Aducanumab Phase 3 Topline Results at AAN Presentation Transcript

May 18, 2020 / 08:00PM GMT
Release Date Price: ARS3060
Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development

Presentation
May 18, 2020 / 08:00PM GMT

=====================
Corporate Participants
=====================
* Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot